GoodRx (GDRX) announced a new partnership with Boehringer Ingelheim to provide discounts for a biosimilar to rheumatoid arthritis drug Humira Thursday, adding to an increasingly competitive market.
The move gives Boehringer more visibility for Cyltezo in what is now a crowded biosimilar market, with 10 products with similar formulations — biologically similar — competing against AbbVie's (ABBV) blockbuster Humira. I heard they will do a zero copay for Cyltezo😁